Moleculin Biotech Receives Nasdaq Notice for Low Bid Price

What Happened
Moleculin Biotech, Inc. (MBRX) announced on Sept. 15, 2026 that Nasdaq’s Listing Qualifications Staff determined the company failed to meet the $1.00 minimum closing bid price required for continued listing on The Nasdaq Capital Market. Nasdaq found the closing bid was below $1.00 for 30 consecutive business days from July 31, 2026 through Sept. 11, 2026 and cited Nasdaq Listing Rule 5550(a)(2). Because the company completed a 1-for-25 reverse stock split on Dec. 1, 2025, it is not eligible for the usual 180-calendar day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Moleculin intends to request a hearing before the Nasdaq Hearings Panel; a timely request will keep the stock trading on Nasdaq while the hearing is pending.

Key Details

• Nasdaq Staff Determination Letter dated Sept. 15, 2026: closing bid below $1.00 for July 31–Sept. 11, 2026 (30 consecutive business days).
• Relevant rules: Nasdaq Listing Rule 5550(a)(2) (minimum bid price) and Rule 5810(c)(3)(A)(iv) (ineligibility for compliance period after a recent reverse split).
• Company effected a 1-for-25 reverse stock split on Dec. 1, 2025, which removed eligibility for the standard 180‑day cure period.
• Moleculin will request a Nasdaq Hearings Panel hearing; a timely request stays any suspension or delisting while the hearing proceeds.

Why It Matters
This filing signals a material listing risk: if Nasdaq ultimately delists the shares, trading liquidity and investor access could be materially affected. For now, the company’s shares will continue to trade because Moleculin plans to seek a hearing, but there is no assurance the request will be granted or that the company will regain compliance. Investors should monitor the company’s stock price, future SEC filings (including the outcome of the hearing), and any additional steps the company may take to regain compliance.